Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Jubilant-Ingrevia-Limited"

7 News Found

Jubilant Ingrevia partners with O2 Renewable to increase use of green energy
News | March 13, 2024

Jubilant Ingrevia partners with O2 Renewable to increase use of green energy

This partnership marks a significant step for the Company towards establishing renewable energy power generation using hybrid open excess through solar and wind sources


Jubilant Ingrevia posts Q2 FY24 consolidated PAT at Rs. 57.49 Cr
News | November 02, 2023

Jubilant Ingrevia posts Q2 FY24 consolidated PAT at Rs. 57.49 Cr

The company has posted net profit of Rs.115.08 crores for half year ended September 30, 202


Jubilant Ingrevia consolidated Q1 FY2024 PAT up QoQ at Rs. 57.59 Cr
News | July 26, 2023

Jubilant Ingrevia consolidated Q1 FY2024 PAT up QoQ at Rs. 57.59 Cr

Jubilant Ingrevia has reported total income of Rs. 1083.52 crores during the period ended June 30, 2023


Jubilant Ingrevia commissions acetic anhydride plant at Bharuch
News | April 20, 2023

Jubilant Ingrevia commissions acetic anhydride plant at Bharuch

This plant adds around 60,000 MT of capacity, scaling Jubilant Ingrevia Limited’s overall annual Acetic Anhydride capacity to 210,000 MT


Jubilant Ingrevia posts Q3FY23 consolidated PAT at Rs. 91.53 Cr
News | February 02, 2023

Jubilant Ingrevia posts Q3FY23 consolidated PAT at Rs. 91.53 Cr

The company has reported total income of Rs. 1165.31 crores during the period ended December 31, 2022


Jubilant Ingrevia to invest Rs. 2,050 crore during FY 22-25
News | November 01, 2022

Jubilant Ingrevia to invest Rs. 2,050 crore during FY 22-25

Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side


CRISIL assigns 'Positive' outlook to Jubilant Pharmova's long-term rating
News | May 11, 2021

CRISIL assigns 'Positive' outlook to Jubilant Pharmova's long-term rating

The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.